RXRX Company Profile and Key Details

Q: Who are the executives of RXRX?

Mr. Ryan KellyManaging DirectorDr. Michael Secora Ph.D.Chief Financial OfficerMs. Tina Marriott LarsonChief Operating Officer & PresMs. Louisa Daniels J.D., M.B.A.Chief Legal Officer & Gen. CounselKevin LeggatVice President of Fin. & AccountingDr. Blake C. Borgeson Ph.D.Co-Founder & DirectorDr. Christopher C. Gibson Ph.D.Co-Founder, Chief Executive Officer & DirectorMr. Benjamin Mabey M.S.Chief Technology OfficerDr. Shafique Virani M.D.Chief Corporation Devel. OfficerMr. Jared AllenbachSenior Director of Investor RelationsMs. Heather Kirkby M.B.A.Chief People Officer

NASDAQ : RXRX

Recursion Pharmaceuticals

$3.72

-0.12-3.13%

At Close 4:00 PM

73.23

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Recursion Pharmaceuticals, Inc. (RXRX) stock declined over -3.13%, trading at $3.72 on NASDAQ, down from the previous close of $3.84. The stock opened at $3.70, fluctuating between $3.63 and $3.81 in the recent session.

Stock Snapshot

3.84

Prev. Close

1.66B

Market Cap

3.63

Day Low

-3.1

P/E Ratio

-1.2

EPS (TTM)

-1.29

Cash Flow per Share

3.7

Open

447.19M

Number of Shares

3.8083

Day High

77.49%

Free Float in %

1.99

Book Value

22.65M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 08, 2026	3.72	3.81	3.63	3.72	22.66M
Jul 07, 2026	3.95	4.05	3.81	3.84	28.78M
Jul 06, 2026	3.78	4.09	3.66	3.96	37.99M
Jul 02, 2026	3.75	3.91	3.70	3.80	32.61M
Jul 01, 2026	3.65	4.04	3.61	3.67	35.66M
Jun 30, 2026	3.68	3.72	3.57	3.67	23.08M
Jun 29, 2026	3.62	3.74	3.55	3.69	22.86M
Jun 26, 2026	3.29	3.62	3.28	3.52	42.5M
Jun 25, 2026	3.24	3.38	3.19	3.34	15.58M
Jun 24, 2026	3.20	3.38	3.16	3.23	15.39M
Jun 23, 2026	3.10	3.27	3.09	3.16	11.07M
Jun 22, 2026	3.20	3.32	3.11	3.18	14.38M
Jun 18, 2026	3.18	3.28	3.11	3.23	24.73M
Jun 17, 2026	3.18	3.34	3.07	3.11	22.08M
Jun 16, 2026	3.27	3.34	3.16	3.18	15.41M
Jun 15, 2026	3.30	3.39	3.23	3.29	15.3M
Jun 12, 2026	3.20	3.30	3.12	3.15	14.78M
Jun 11, 2026	3.00	3.16	2.95	3.15	25.3M
Jun 10, 2026	3.15	3.28	3.03	3.04	19.38M
Jun 09, 2026	3.33	3.49	3.13	3.22	17.79M

Contact Details

Salt Lake City, UT 84101

United States

https://www.recursion.com 385 269 0203

About Company

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Stock Peers

ARGX

-4.64-0.50%

argenx SE$915.30 REGN

-13.35-1.97%

Regeneron Pharmaceuticals, Inc.$662.88 MDGL

20.04+3.67%

Madrigal Pharmaceuticals, Inc.$565.40 UTHR

-9.36-1.66%

United Therapeutics Corporation$554.34 VRTX

-23.82-4.56%

Vertex Pharmaceuticals Incorporated$498.43 KRYS

6.8+1.84%

Krystal Biotech, Inc.$375.40 PRAX

9.04+2.79%

Praxis Precision Medicines, Inc.$332.99 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.91+0.59%

Alnylam Pharmaceuticals, Inc.$323.50 LGND

-4.55-1.42%

Ligand Pharmaceuticals Incorporated$314.88

Company Overview

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) closed at $3.72 USD, losing -$0.12 (-3.12%) from the previous close of $3.84. The stock is currently mid-range between its 52-week high and low $2.77 and $7.18. With a market capitalization of about $1.66 billion, Recursion Pharmaceuticals, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.99). Key stats such as the average daily volume over the past year has been around 18.20 million shares, in line with its 52-week average. Headquartered in Salt Lake City, UT, Recursion Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Najat Khan, the company employs approximately 600 people and listed since April 16, 2021. Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -0.07%, SMA50 -10.38%, SMA200 -22.56%). The stock’s 14-day RSI is 46.4 (neutral), while the ATR of 0.3 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -56.62% below its high and over 26.51% above its low. Average 10-day trading volume of 29.09 million shares is significantly above the 3-month average of 18.36 million, indicating heightened recent market interest.

Valuation Metrics

Recursion Pharmaceuticals, Inc. trades at a P/E ratio of -3.08, slightly below the S&P 500 average, with a price-to-sales ratio of 24.93 and a price-to-book ratio of 1.91 suggesting the stock is closer to book value. The P/FCF stands at -5.07, also above market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Recursion Pharmaceuticals, Inc. generated EPS of -$1.48 over the past year. Five-year average earnings growth is -22.39%. The latest quarter delivered EPS of -$0.22. The next quarter is forecast at -$0.26. Next year's EPS is expected at -$14.17. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $11.00 to $5.50. The high target offers 195.7% upside. The low target suggests 47.85% downside. The mean target is $8.21. This offers 120.7% upside. Recursion Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by -26.67%. The prior quarter beat by -25.0%. Over the last six quarters, Apple has recorded several small beats. These include 20.45% in February 28, 2025.

Shareholding & Insider Activity

Recursion Pharmaceuticals, Inc. has 429.71 million shares outstanding. The public float is 416.22 million shares, elevated short interest at 30.22% of float. This equals 122.22 million shares. The short ratio is 4.63 days. Institutional investors hold 70.45% of the float. Insiders own 2.36%. Borgeson Blake holds 6.17 million shares, Khan Najat has 2.18 million shares and Secora Michael has 1.50 million shares. Over the past six months, insider transactions show net selling. They sold 921.62 thousand shares across 20 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Recursion Pharmaceuticals generated $44.58M in revenue, or $0.21 per share. Gross margin was -14.61%, operating margin -785.33%, and net profit margin -735.99%. Returns are negative, with ROA at -50.19% and ROE at -70.79%.
On valuation metrics, Recursion Pharmaceuticals trades at a P/E of -3.08, P/S of 24.93 and P/B of 1.91. The current ratio is 5.47 and quick ratio is 5.47. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -8.53 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.07, supported by a cash flow-to-debt ratio of -4.43.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Recursion Pharmaceuticals posted revenue of $44.58M, down slightly from $39.68M in the prior quarter. Gross profit was - $6.51M (margin -14.61%). Operating income was - $350.06M (margin -785.3%). Net income was- $328.07M (EPS - $1.58).
The company ended the quarter with $394.80M in cash and short-term investments, a total debt of $50.67M, and net debt of - $344.12M. Total assets were $653.70M, with equity of $463.44M. Financials further reflected weakness, with operating cash flow of - $287.78M, free cash flow of - $300.33M, and capital expenditures of - $12.55M.

Price Forecast & Outlook

Our AI price prediction model suggests that Recursion Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.45%, with price expected at $3.96 by July 22, 2026, within a range of $3.72 to $4.26 3-Month Outlook: Projected fall of -12.37%, reaching $3.26 by October 06, 2026, with a range of $3.00 to $3.50. 1-Year Outlook: Projected gain of 14.25%, with price at $4.25 by July 08, 2027, within a range of $0.00 to $1.92.

Key Takeaways

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares are flat 7.58% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Recursion Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -3.08. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $12.42, suggesting 233.87% upside. Our AI forecast model points to short-term strength (6.45% over two weeks), a medium-term fall (-12.37% over three months), and a longer-term gain (14.25% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Recursion Pharmaceuticals, Inc. (RXRX) stock price?

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock price is $3.72 in the last trading session. During the trading session, RXRX stock reached the peak price of $3.81 while $3.63 was the lowest point it dropped to. The percentage change in RXRX stock occurred in the recent session was -3.13% while the dollar amount for the price change in RXRX stock was - $0.12.

RXRX's industry and sector of operation?

The NASDAQ listed RXRX is part of Biotechnology industry that operates in the broader Healthcare sector. Recursion Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RXRX?

Mr. Ryan Kelly
Managing Director
Dr. Michael Secora Ph.D.
Chief Financial Officer
Ms. Tina Marriott Larson
Chief Operating Officer & Pres
Ms. Louisa Daniels J.D., M.B.A.
Chief Legal Officer & Gen. Counsel
Kevin Leggat
Vice President of Fin. & Accounting
Dr. Blake C. Borgeson Ph.D.
Co-Founder & Director
Dr. Christopher C. Gibson Ph.D.
Co-Founder, Chief Executive Officer & Director
Mr. Benjamin Mabey M.S.
Chief Technology Officer
Dr. Shafique Virani M.D.
Chief Corporation Devel. Officer
Mr. Jared Allenbach
Senior Director of Investor Relations
Ms. Heather Kirkby M.B.A.
Chief People Officer

How RXRX did perform over past 52-week?

RXRX's closing price is 34.3% higher than its 52-week low of $2.77 where as its distance from 52-week high of $7.18 is -48.19%.

How many employees does RXRX have?

Number of RXRX employees currently stands at 800.

Link for RXRX official website?

Official Website of RXRX is: https://www.recursion.com

How do I contact RXRX?

RXRX could be contacted at phone 385 269 0203 and can also be accessed through its website. RXRX operates from 41 South Rio Grande Street, Salt Lake City, UT 84101, United States.

How many shares of RXRX are traded daily?

RXRX stock volume for the day was 22.65M shares. The average number of RXRX shares traded daily for last 3 months was 18.2M.

What is the market cap of RXRX currently?

The market value of RXRX currently stands at $1.66B with its latest stock price at $3.72 and 447.19M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	800
Beta	1
Sales or Revenue	$44.58M
5Y Sales Change%	19.78%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RXRX Company Profile and Key Details

Recursion Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Dividend & Fair Value

Earnings & Analyst Outlook

Valuation Metrics

Shareholding & Insider Activity

Key Takeaways

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights